APA (7th ed.) Citation

SV, L., RA, B., YH, K., D, C., A, N., & V, V. (2025). 5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC. Immunotherapy, 17(14), 1005. https://doi.org/10.1080/1750743X.2025.2569856

Chicago Style (17th ed.) Citation

SV, Liu, Babel RA, Kao YH, Chirovsky D, Namakydoust A, and Velcheti V. "5-year Real-world Outcomes with First-line Pembrolizumab Plus Chemotherapy in Advanced/metastatic NSCLC." Immunotherapy 17, no. 14 (2025): 1005. https://doi.org/10.1080/1750743X.2025.2569856.

MLA (9th ed.) Citation

SV, Liu, et al. "5-year Real-world Outcomes with First-line Pembrolizumab Plus Chemotherapy in Advanced/metastatic NSCLC." Immunotherapy, vol. 17, no. 14, 2025, p. 1005, https://doi.org/10.1080/1750743X.2025.2569856.